Challenge Yourself and Impact the Future! Element Solutions Inc (NYSE:ESI) is a leading specialty chemicals company whose operating businesses formulate a broad range of solutions that enhance the performance of products people use every day. Developed
Challenge Yourself and Impact the Future! Element Solutions Inc (NYSE:ESI) is a leading specialty chemicals company whose operating businesses formulate a broad range of solutions that enhance the performance of products people use every day. Developed
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
At EY, we’re all in to shape your future with confidence. We’ll help you succeed in a globally connected powerhouse of diverse teams and take your career wherever you want it to go. Join EY and
Job Description SummaryThe Japan Program Clinical Head (JPCH) is responsible for clinical program activities for approval and post approval commitment for Re-examination in Japan. The JPCH is responsible for one or more clinical programs across indications,
General Information Job Advert Title: Senior Scientist, Applied Safety JP, Applied Safety Location: Tsukuba, Ibaraki Division: Early Development and Translational Science Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
企業概要 WD is building the infrastructure behind the AI-driven data economy. As AI scales, so does data. Every interaction, every model, every system generates data that must be stored, managed, and made accessible over time. That’s where
Company Description WD is building the infrastructure behind the AI-driven data economy. As AI scales, so does data. Every interaction, every model, every system generates data that must be stored, managed, and made accessible over time. That’s
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Job Description SummaryDrive regulatory submission excellence and early-stage development strategy by authoring high-quality Japanese New Drug Applications and providing pharmacology or toxicology expertise to clinical programs in Japan. Job Description 職務内容 非臨床安全性担当者としてプロジェクトチームに参画しチームメンバーと協働し開発を推進する。 Globalメンバーの一員として，国内外の開発に非臨床安全性担当者として貢献する。 主な役割責任 早期化合物の安全性評価を行いチームへ適切に評価内容を伝える。 承認申請資料を作成し，当局からの照会回答を含む承認申請全般に責任をもつ。 治験届に関する資料作成を行い，当局からの照会対応を含む治験届業務全般に責任をもつ。